Valneva SE Sponsored ADR is an American depositary receipt representing shares of Valneva SE, a specialty vaccine company focused on the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. Valneva’s current portfolio includes vaccines for travel and endemic disease prevention, serving public health, travel medicine, and infectious disease markets. The company works across research, clinical development, manufacturing, and commercialization, giving it an integrated role in bringing vaccines from development to market. Its business is centered on specialty immunization products designed for targeted patient groups and healthcare providers, with a focus on prevention rather than treatment. Valneva SE is headquartered in Saint-Herblain, France.
Website6 rue Alain Bombard
Saint-Herblain, 44800
France
Detailed price information for Valneva Se ADR (VALN-Q) from The Globe and Mail including charting and trades.
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Pfizer (NYSE:PFE) and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405. The validation starts the EMA regulatory assessment process for what could become a first in class Lyme disease vaccine for use in both North America and Europe. The application is supported by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This move by...
Detailed price information for Valneva Se ADR (VALN-Q) from The Globe and Mail including charting and trades.
Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...
Investors talking about VALN also mention
What share of all stock conversation is about VALN?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% new | 0% 0 | 0% +0 |
Of the messages about VALN that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% +45 | 84.43% +0.39 | ||
| Bearish | — | — | 0% -45 | 15.57% -0.39 |
Of the messages about VALN that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | — | 83.04% | ||
| Analysts | — | — | — | 10.43% | ||
| Technical Analysis | — | — | — | 1.74% | ||
| Controversies | — | — | — | 1.3% | ||
| Earnings | — | — | — | 3.48% | ||
| Macro | — | — | — | 0% |
Of the messages about VALN, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 98.48% | 96.43% | 21.06% | ||
| Newcomers | 100% | 1.52% | 3.57% | 78.94% |